#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average by	urden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Finit of Typ.	e Responses	)														
Name and Address of Reporting Person *  Mendelsohn Aaron			2. Issuer Name and Ticker or Trading Symbol SECOND SIGHT MEDICAL PRODUCTS INC [EYES]						~	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner Officer (give title below) Other (specify below)						
	(Last) (First) (Middle) 2744 SAN FERNANDO ROAD, SUITE 400				3. Date of Earliest Transaction (Month/Day/Year) 06/01/2018											
(Street)  SYLMAR, CA 91342  (City) (State) (Zip)			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
		(Suite)		Table I - Non-Derivative Securities Acqu							uired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, i any (Month/Day/Yea		Date, if	Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		f (D) Ov Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		d (	Ownership of Form:	'. Nature of Indirect Beneficial	
					ay/Year)	Code	e V	Amount (A) or		Price (In	(Instr. 3 and 4)		c (	r Indirect	Ownership (Instr. 4)	
СОММО	N STOCK		06/01/2018				A	2	9,442	A		3,807		I	Í	
	•		class of securities be	chenelan	iy ov	viied dire	ctry or r	Persons in this f	orm are	not rec	quired to	respond u		on contained form display		474 (9-02)
	•						•	Persons in this f a currer	orm are itly valid	not red	quired to control r	respond u number.				474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction	Table II - 3A. Deemed Execution Date, if any	- Deriva ( <i>e.g.</i> , pu	tive s	Securitie calls, war  5. Numb of Deriv Securitie Acquire or Dispo of (D)	s Acquirants, of the set of the s	Persons in this f a currer ired, Dispo options, con	orm are atly valid sed of, or	not red d OMB r Benefic securiti	quired to control r cially Ow ies)	ned and Amount lying	8. Price of	9. Number of Derivative Securities Beneficially Owned Following	10. Ownersh Form of Derivativ Security Direct (I	11. Natur of Indired Beneficiae Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	- Derivat (e.g., pt 4. Transac Code	tive s	Securitie calls, war  5. Numb of Deriv Securitie Acquire or Dispo	s Acquirants, coer 6 attive Ees (I (A) ssed 4,	Persons in this for a currer ired, Dispo options, cores. Date Exercise Expiration D	orm are atly valid sed of, or	not recd OMB  r Benefit securiti nd	cially Owies) 7. Title arof Under Securities	ned Amount lying s and 4)  Amount or Number	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned	10. Ownersh Form of Derivativ Security Direct (I or Indire	ip of Indired Beneficial Ownersh (Instr. 4)
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	- Derivat (e.g., pt 4. Transac Code	tive s	Securitie alls, war  5. Numb of Deriv Securitie Acquire or Dispc of (D) (Instr. 3,	s Acquirants, coer 6 attive Ees (I (A) ssed 4,	Persons in this for a currer ired, Dispoortions, corp. Date Exerexpiration D Month/Day/	erm are titly valid sed of, or twertible cisable ar ate Year)	not recd OMB  r Benefit securiti nd	cially Owness 7. Title au of Under Securities (Instr. 3 a	respond unumber.  ned  and Amount lying s s and 4)  Amount or	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownersh Form of Derivati Security Direct (I or Indire	ip of Indired Beneficial Ownersh (Instr. 4)

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Mendelsohn Aaron 12744 SAN FERNANDO ROAD SUITE 400 SYLMAR, CA 91342	X					

## **Signatures**

/s/ John T. Blake, Attorney	y-in-fact	06/05/2018
***Signature of Reporting Person	n	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Awarded as compensation for serving on the Board of Directors and its committees.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### POWER OF ATTORNEY

(FOR EXECUTING FORM ID, FORMS 3, 4 AND 5 AND SCHEDULES 13D AND 13G)

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints John Blake and Scott Dunbar, or either of them, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

- (i) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the Securities and Exchange Commission of reports required by Section 13(d) and Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rules or regulations promulgated thereunder;
- (ii) prepare, execute and file, for and on behalf of the undersigned with respect to holdings of and transactions in securities issued by a company to the undersigned or Second Sight Medical Products, Inc. any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any stock exchange or similar authority, under the Exchange Act, including without limitation (a) any Joint Filing Agreement under Rule 13d-1(k) of the Exchange Act (or any successor provision thereunder), Schedule 13D and Schedule 13G (or any successor schedules or forms adopted under the Exchange Act) and any amendments thereto in accordance with Section 13 of the Exchange Act and the rules thereunder, and (b) Forms 3, 4 and 5 and any amendments thereto in accordance with Section 16(a) of the Exchange Act and the rules thereunder: and
- (iii) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact in serving in such capacity at the request of the undersigned, are not assuming, nor is Second Sight Medical Products, Inc. assuming, any of the undersigned's responsibilities to comply with the Exchange Act, including without limitation Sections 13 and 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file any form or document with respect to the undersigned's holdings of and transactions in securities issued by a company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-infact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by (or ceases to be a Director of) Second Sight Medical Products, Inc.

I hereby declare that any act or thing lawfully done hereunder by the foregoing attorneys-in-fact shall be binding on the undersigned as if done by myself.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 27th day of March, 2018.

/s/ Aaron Mendelsohn
Aaron Mendelsohn